Previously, Valeant signed a deal to take over Lithuania-based specialty pharmaceuticals company AB Sanitas for around EUR314m.
Sanitas has a range of branded generics product portfolio consisting of 390 products in nine countries throughout Central and Eastern Europe, primarily Poland, Russia and Lithuania.
The company has in-house development capabilities in dermatology, ophthalmology and hospital injectables and also a pipeline of internally developed and acquired dossiers.